Argenx's (ARGX) Vyvgart remains the fastest-growing treatment for chronic inflammatory demyelinating polyneuropathy, or CIDP, with its patient share expected to rise to 23% from 18%, Wedbush Securities said Thursday in a report.

Survey results by Wedbush support Argenx's Vyvgart revenue forecasts of $1.3 billion for Q1 and $5.8 billion for 2026, including $2 billion from CIDP and $3.8 billion from generalized myasthenia gravis, according to the report.

Wedbush said it sees additional upside from potential near-term approvals in seronegative and ocular myasthenia gravis, which could broaden the number of patients eligible for the drug.

Argenx offers an attractive opportunity given its growth outlook and current valuation, the report said.

Wedbush maintained its outperform rating on Argenx stock with a $1,000 price target.

Q1 results are due May 7.

Price: 828.68, Change: -12.19, Percent Change: -1.45